Literature DB >> 3734770

Successful use of clonazepam in patients with treatment-resistant panic disorder.

G E Tesar, J F Rosenbaum.   

Abstract

Ten cases are presented--two in detail--in which clonazepam was used successfully in patients with treatment-resistant panic disorder with or without agoraphobia. Seven of 10 patients who had been resistant to standard pharmacological treatments of panic attacks and agoraphobia achieved cessation of their attacks while three had mild to moderate symptom persistence. These data underscore other reports of clonazepam's usefulness in the treatment of panic disorder. Clinical use of clonazepam is discussed.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3734770     DOI: 10.1097/00005053-198608000-00006

Source DB:  PubMed          Journal:  J Nerv Ment Dis        ISSN: 0022-3018            Impact factor:   2.254


  9 in total

1.  Algorithm for the pharmacotherapy of anxiety disorders.

Authors:  Dan J Stein
Journal:  Curr Psychiatry Rep       Date:  2003-08       Impact factor: 5.285

Review 2.  The Black Book of Psychotropic Dosing and Monitoring.

Authors:  Alan F Schatzberg; DeBattista Charles
Journal:  Psychopharmacol Bull       Date:  2018-01-15

Review 3.  Overview of panic disorder.

Authors:  J C Ballenger
Journal:  Trans Am Clin Climatol Assoc       Date:  1994

Review 4.  Etiology, triggers and neurochemical circuits associated with unexpected, expected, and laboratory-induced panic attacks.

Authors:  Philip L Johnson; Lauren M Federici; Anantha Shekhar
Journal:  Neurosci Biobehav Rev       Date:  2014-08-15       Impact factor: 8.989

Review 5.  An animal model of panic vulnerability with chronic disinhibition of the dorsomedial/perifornical hypothalamus.

Authors:  Philip L Johnson; Anantha Shekhar
Journal:  Physiol Behav       Date:  2012-03-26

6.  OREXIN 1 AND 2 RECEPTOR INVOLVEMENT IN CO2 -INDUCED PANIC-ASSOCIATED BEHAVIOR AND AUTONOMIC RESPONSES.

Authors:  Philip L Johnson; Lauren M Federici; Stephanie D Fitz; John J Renger; Brock Shireman; Christopher J Winrow; Pascal Bonaventure; Anantha Shekhar
Journal:  Depress Anxiety       Date:  2015-08-19       Impact factor: 6.505

7.  A risk-benefit assessment of pharmacological treatments for panic disorder.

Authors:  J A Bennett; M Moioffer; S P Stanton; M Dwight; P E Keck
Journal:  Drug Saf       Date:  1998-06       Impact factor: 5.606

8.  Evaluation of JNJ-54717793 a Novel Brain Penetrant Selective Orexin 1 Receptor Antagonist in Two Rat Models of Panic Attack Provocation.

Authors:  Pascal Bonaventure; Christine Dugovic; Brock Shireman; Cathy Preville; Sujin Yun; Brian Lord; Diane Nepomuceno; Michelle Wennerholm; Timothy Lovenberg; Nicolas Carruthers; Stephanie D Fitz; Anantha Shekhar; Philip L Johnson
Journal:  Front Pharmacol       Date:  2017-06-09       Impact factor: 5.810

9.  Aligning the many definitions of treatment resistance in anxiety disorders: A systematic review.

Authors:  Wicher A Bokma; Guido A A M Wetzer; Jurriaan B Gehrels; Brenda W J H Penninx; Neeltje M Batelaan; Anton L J M van Balkom
Journal:  Depress Anxiety       Date:  2019-06-23       Impact factor: 6.505

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.